Boston Scientific’s Strong Market Position and Innovative Pipeline Drive Buy Rating

Analyst Larry Biegelsen of Wells Fargo maintained a Buy rating on Boston Scientific (BSX – Research Report), retaining the price target of $118.00.

Larry Biegelsen has given his Buy rating due to a combination of factors that highlight Boston Scientific’s strong position in the medical technology sector. The company is expected to maintain its leadership in pulsed field ablation (PFA) through its experienced research and development team, extensive clinical data, and innovative product pipeline. Boston Scientific’s Farawave catheter is noted for its simplicity, flexibility, efficiency, and safety, making it a standout as the ablation field evolves.
Additionally, the upcoming products such as Farapoint and the next-generation Farawave are poised to address specific medical needs, including atrial flutter ablation and more complex procedures. The company’s strategic focus on enhancing procedure efficacy and reducing the need for re-do ablations further strengthens its market position. These factors, combined with the synergies from its cardiac rhythm management portfolio, contribute to the positive outlook and Buy rating.

Biegelsen covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Dexcom, and Medtronic. According to TipRanks, Biegelsen has an average return of 6.8% and a 55.60% success rate on recommended stocks.